Ind-Swift Laboratories Q1 FY27: Revenue Up 21%, EBITDA Margin Expands to 17.91%
Ind-Swift Laboratories reported Q1 FY27 revenue of ₹186.08 crore, up 21.16% YoY. EBITDA margin expanded to 17.91% from 5.33%. CDMO partnerships are expected to contribute ₹200-220 crore in FY27. The company plans ₹250 crore capex over 2.5 years and targets ₹1500 crore revenue by FY30.
The announcement details significant revenue growth, margin expansion, and strategic progress in the CDMO business, which are material financial and operational developments for the company. The clear future growth guidance and capex plans also indicate a high impact.
The company reported strong year-on-year growth in revenue and significant expansion in EBITDA and PAT margins. The commercialization of CDMO partnerships and positive outlook for future growth contribute to a positive sentiment.
Ind-Swift Laboratories Limited has reported a strong performance for the first quarter of FY27, with operating income growing by 21.16% year-on-year to ₹186.08 crore. The company's transformation into a focused Finished Dosage Formulation (FDF) manufacturer is showing positive results.
Operationally, the quarter saw the commercialization of CDMO partnerships with Viatris, Manx, and Arrotex, which are expected to contribute an incremental revenue of ₹200 to ₹220 crore in FY27. Two new products, Ibuprofen Sachet and Macrogol Sachet, were also commercialized for European and UK/Australian markets, respectively. The company's total filed dossiers increased to over 2,100, and global product registrations reached over 850.
The revenue mix continues to shift towards exports, which constituted 57.20% of quarterly sales in Q1 FY27, up from 48% in Q1 FY26. Contract manufacturing within exports accounted for 26.64% of sales. The company highlighted strong growth in key export molecules such as Atorvastatin (₹85.50 crore in FY26) and Ezetimibe + Atorvastatin (₹80.78 crore in FY26, with 246.97% year-on-year growth). Upcoming launches include Clarithromycin dry suspension and Esomeprazole.
Financially, Operating EBITDA improved significantly to ₹33.32 crore from ₹8.66 crore in the prior year, with EBITDA margins expanding by 1258 basis points to 17.91%. Profit After Tax (PAT) excluding exceptional items rose to ₹24.68 crore, a 2.04x jump from ₹8.12 crore, with PAT margins improving to 13.26%.
During the earnings call, management discussed the CDMO partnership's initial contribution of ₹5-6 crore, with expectations of ₹100-130 crore in the current fiscal year and gradual increase over two years. The company plans to deploy its ₹250 crore cash reserves in capex over 2.5 years, focusing on expanding manufacturing facilities and warehouses. The company also confirmed it has no immediate plans to divest its stake in Synthimed.
Looking ahead, Ind-Swift Laboratories aims for a revenue of ₹1500 crore and a net profit of over ₹200 crore by FY30, with sustainable EBITDA margins of 18-22%. The company anticipates achieving EBITDA margins exceeding 20% by the third quarter of FY27. Future capex will be a mix of own-brand and CDMO initiatives, with an estimated ₹50-75 crore capex for new CDMO partnerships expected to generate over ₹150 crore in revenue.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.